40
Immuno Cancer Biotherapeutics raises indefinite capital under Reg D 506(b) in Delaware biotech startup
Company raise · Open-ended · CANTON, SD · Form D filed 2026-10-15
Immuno Cancer Biotherapeutics, a Delaware corporation incorporated in 2024, is raising an indefinite amount under Regulation D 506(b) exemption. The company has sold $75K to three investors as of October 9, 2026.
Note: New issuer on EDGAR; indefinite offering amount; minimal capital raised to date ($75K) suggests very early stage.
First raise on EDGARoperating_company
Why now — by persona
- Executive & technical recruiting:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock
- B2B software & services sales:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock
- Commercial banking / treasury:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock
- D&O and management-liability insurance:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock
- Outsourced accounting / CFO:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock
People on the filing
| James Robl | Executive Officer, Director |
| Stephen Collins | Director |
Signed by James Robl, Executive Chairman.
Filing contact
The issuer's phone number and address from the filing are shown to subscribers. See plans, or read it on EDGAR.